Med24
overweight-obesity 29. 5. 2025 • 2 min read • Cells

Role of microRNAs in Osteosarcopenic Obesity/Adiposity: A Scoping Review

Background: Osteosarcopenic obesity (OSO) syndrome, also defined as osteosarcopenic adiposity (OSA), is characterized by the concurrent loss of bone and muscle mass, accompanied by excess fat, leading to reduced functionality and metabolic imbalances. Recent studies have highlighted the role of microRNAs (miRNAs) in...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

Osteosarcopenic obesity (OSO) syndrome, also defined as osteosarcopenic adiposity (OSA), is characterized by the concurrent loss of bone and muscle mass alongside excess fat, resulting in reduced functionality and metabolic imbalances. Research indicates differential expression of microRNAs (miRNAs) in individuals with osteosarcopenia and obesity.

Study Methodology

A scoping review was conducted, examining 19 studies that met eligibility criteria following a comprehensive search of international bibliographic databases including Embase, PubMed, and Scopus. The search initially yielded 1311 records.

Sponsored content

Key Findings and Future Directions

The review highlights the influence of physical exercise and nutritional factors on miRNA expression, emphasizing their potential role in promoting better health outcomes in aging populations. Animal studies have documented the critical role of miRNAs as indicators of muscle atrophy and the biological processes associated with aging and sarcopenia. These studies suggest that targeted interventions, such as resistance training and lifelong exercise, may effectively influence miRNA expression. Further investigation into these findings could lead to the development of biomarkers and therapeutic targets for managing OSO/OSA.

Original Scientific Source
Cells
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
overweight-obesity

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

28. 10. 2026 Read article →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial
overweight-obesity

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

14. 10. 2026 Read article →
Advertisement